(VIANEWS) – MELHUS SPAREBANK (MELG.OL), MEDISTIM (MEDI.OL), MERCK AND CO INC (MRK.PA) are the highest payout ratio stocks on this list.
We have collected information about stocks with the highest payout ratio as yet. The payout ratio in itself isn’t a guarantee of good investment but it’s an indicator of whether dividends are being paid and how the company chooses to issue them.
When researching a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.
1. MELHUS SPAREBANK (MELG.OL)
82.55% Payout Ratio
Melhus Sparebank, a savings bank, provides various banking products and services to companies, agriculture customers, and private individuals in Norway. The company offers savings accounts; construction and business loans; bank guarantee, overdraft, and leasing services; and credit and bank cards. It also provides various insurance products for liability, health, personnel, occupational injury, travel, accident, business, store, data attack, property damage, craftsman, homeowners, office, vehicle, and farms; savings and pension products; payment services; and online and mobile banking services. The company operates through branch offices in central Trondheim, Heimdal, Ler, and Korsvegen. Melhus Sparebank was founded in 1840 and is headquartered in Melhus, Norway.
Earnings Per Share
As for profitability, MELHUS SPAREBANK has a trailing twelve months EPS of kr12.72.
PE Ratio
MELHUS SPAREBANK has a trailing twelve months price to earnings ratio of 12.58. Meaning, the purchaser of the share is investing kr12.58 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.04%.
Moving Average
MELHUS SPAREBANK’s value is under its 50-day moving average of kr166.16 and under its 200-day moving average of kr160.05.
Sales Growth
MELHUS SPAREBANK’s sales growth is 14.5% for the ongoing quarter and negative 13.7% for the next.
More news about MELHUS SPAREBANK.
2. MEDISTIM (MEDI.OL)
59.15% Payout Ratio
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally. It offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; and imaging probes for intraoperative use. The company also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, it distributes and sells third party medical equipment. The company was incorporated in 1984 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, MEDISTIM has a trailing twelve months EPS of kr6.39.
PE Ratio
MEDISTIM has a trailing twelve months price to earnings ratio of 45.7. Meaning, the purchaser of the share is investing kr45.7 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 31.89%.
Sales Growth
MEDISTIM’s sales growth is 15.7% for the present quarter and 16.7% for the next.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Apr 25, 2023, the estimated forward annual dividend rate is 4.5 and the estimated forward annual dividend yield is 1.57%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is a negative 17.7% and positive 11.1% for the next.
Yearly Top and Bottom Value
MEDISTIM’s stock is valued at kr292.00 at 12:10 EST, way below its 52-week high of kr330.00 and way higher than its 52-week low of kr184.80.
More news about MEDISTIM.
3. MERCK AND CO INC (MRK.PA)
55.47% Payout Ratio
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Earnings Per Share
As for profitability, MERCK AND CO INC has a trailing twelve months EPS of €4.72.
PE Ratio
MERCK AND CO INC has a trailing twelve months price to earnings ratio of 22.37. Meaning, the purchaser of the share is investing €22.37 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.69%.
Yearly Top and Bottom Value
MERCK AND CO INC’s stock is valued at €105.60 at 12:10 EST, below its 52-week high of €110.00 and way higher than its 52-week low of €77.30.
Revenue Growth
Year-on-year quarterly revenue growth declined by 8.9%, now sitting on 57.87B for the twelve trailing months.
Moving Average
MERCK AND CO INC’s value is above its 50-day moving average of €102.80 and higher than its 200-day moving average of €98.87.
Earnings Before Interest, Taxes, Depreciation, and Amortization
MERCK AND CO INC’s EBITDA is 4.75.
More news about MERCK AND CO INC.
4. SANOFI (SAN.PA)
50.08% Payout Ratio
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, SANOFI has a trailing twelve months EPS of €6.77.
PE Ratio
SANOFI has a trailing twelve months price to earnings ratio of 14.94. Meaning, the purchaser of the share is investing €14.94 for every euro of annual earnings.
Moving Average
SANOFI’s worth is higher than its 50-day moving average of €98.11 and way higher than its 200-day moving average of €88.92.
More news about SANOFI.
5. RETAIL ESTATES (RET.BR)
31.81% Payout Ratio
The Belgian public real estate investment trust Retail Estates nv is a niche player specialised in making in out-of-town retail properties located on the periphery of residential areas or along main access roads to urban centres available to users. Real Estates NV acquires these real properties from third parties or builds and commercialises retail buildings for its own account. The buildings have useful areas ranging between 500m² and 3,000m². A typical retail building has an average area of 1,000 m². As of 31 December 2022, Retail Estates nv has 1,012 properties in its portfolio with a total retail area of 1,207,542 m², spread over Belgium and the Netherlands. The occupancy rate of the portfolio was 97.92% on 31 December 2022, compared to 97.83% on 31 March 2022. The fair value of the consolidated real estate portfolio of Retail Estates NV on 31 December 2022 is estimated at € 1,855 million by independent real estate experts. Retail Estates NV is listed on Euronext Brussels and Euronext Amsterdam and is registered as a public regulated real estate company.
Earnings Per Share
As for profitability, RETAIL ESTATES has a trailing twelve months EPS of €14.17.
PE Ratio
RETAIL ESTATES has a trailing twelve months price to earnings ratio of 4.52. Meaning, the purchaser of the share is investing €4.52 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.3%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jul 28, 2023, the estimated forward annual dividend rate is 4.9 and the estimated forward annual dividend yield is 7.62%.
More news about RETAIL ESTATES.
